Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2

Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works

<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413 · see citing works

Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,434 · see citing works

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251 · see citing works

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904 · see citing works

Tumour-intrinsic resistance to immune checkpoint blockade

Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,491 · see citing works

Immune-related adverse events of checkpoint inhibitors

Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966 · see citing works

Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii , a commensal bacterium deficient in Crohn’s disease

Quévrain, E., Maubert, M.-A., Michon, C., Chain, F., Marquant, R., Tailhades, J., Miquel, S., Carlier, L., Bermúdez‐Humarán, L. G., Pigneur, B., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307649 · Cited by 861 · see citing works

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · see citing works

<i>Akkermansia muciniphila</i> induces intestinal adaptive immune responses during homeostasis

Ansaldo, E., Slayden, L. C., Ching, K. L., Koch, M. A., Wolf, N. K., Plichta, D. R., Brown, E. M., Graham, D. B., Xavier, R. J., Moon, J. J., et al. (2019) · Science · doi:10.1126/science.aaw7479 · Cited by 566 · see citing works

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.001 · Cited by 484 · see citing works

Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue

Weigmann, B., Tubbe, I., Seidel, D., Nicolaev, A., Becker, C., & Neurath, M. F. (2007) · Nature Protocols · doi:10.1038/nprot.2007.315 · Cited by 483 · see citing works

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480 · see citing works

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01406-6 · Cited by 437 · see citing works

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396 · see citing works

<i>Enterococcus</i> peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy

Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C. (2021) · Science · doi:10.1126/science.abc9113 · Cited by 366 · see citing works

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Hailemichael, Y., Johnson, D. H., Abdel‐Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 365 · see citing works

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351 · see citing works

Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 303 · see citing works

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01965-2 · Cited by 256 · see citing works

<i>Bifidobacterium</i> can mitigate intestinal immunopathology in the context of CTLA-4 blockade

Wang, F., Yin, Q., Chen, L., & Davis, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712901115 · Cited by 223 · see citing works

Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors

Montalban‐Arques, A., Katkeviciutė, E., Busenhart, P., Bircher, A., Wirbel, J., Zeller, G., Morsy, Y., Borsig, L., Garzon, J. F. G., Mueller, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.08.001 · Cited by 197 · see citing works

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice

Sanmamed, M. F., Rodríguez, I., Schalper, K. A., Oñate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., Morales‐Kastresana, A., Labiano, S., Perez‐Gracia, J. L., Martín‐Algarra, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3510 · Cited by 172 · see citing works

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite

Renga, G., Nunzi, E., Pariano, M., Puccetti, M., Bellet, M. M., Pieraccini, G., D’Onofrio, F., Santarelli, I., Stincardini, C., Aversa, F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003725 · Cited by 144 · see citing works

Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction

Alameddine, J., Godefroy, E., Papargyris, L., Sarrabayrouse, G., Tabiasco, J., Bridonneau, C., Yazdanbakhsh, K., Sokol, H., Altare, F., & Jotereau, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00143 · Cited by 119 · see citing works

Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines

Reschke, R., Shapiro, J. W., Yu, J., Rouhani, S. J., Olson, D. J., Zha, Y., & Gajewski, T. F. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0362 · Cited by 82 · see citing works

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 62 · see citing works

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota

Hu, Z. I., Link, V. M., Lima-Junior, D. S., Delaleu, J., Bouladoux, N. J., Han, S., Collins, N., & Belkaid, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200348119 · Cited by 58 · see citing works

Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation

Huang, X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i22.5201 · Cited by 57 · see citing works

ZFP90 drives the initiation of colitis-associated colorectal cancer via a microbiota-dependent strategy

Han, J., Tao, Z., Qian, Y., Yu, C., Li, J., Kang, Z., Lu, S., Xie, Y., Hong, J., Chen, H., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1917269 · Cited by 35 · see citing works

Microbiome influencers of checkpoint blockade–associated toxicity

Wang, Y., Jenq, R. R., Wargo, J. A., & Watowich, S. S. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220948 · Cited by 34 · see citing works

<i>Faecalibacterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitors

Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2374954 · Cited by 74 · see citing works

Faecalibacterium prausnitzii and human intestinal health

Miquel, S., Martín, R., Rossi, O., Bermúdez‐Humarán, L. G., Chatel, J., Sokol, H., Thomas, M., Wells, J. M., & Langella, P. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.003 · Cited by 1,239 · see citing works

Butyrate mediates anti-inflammatory effects of <i>Faecalibacterium prausnitzii</i> in intestinal epithelial cells through <i>Dact3</i>

Lenoir, M., Martín, R., Torres-Maravilla, E., Chadi, S., González-Dávila, P., Sokol, H., Langella, P., Chain, F., & Bermúdez-Humarán, L. G. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1826748 · Cited by 245 · see citing works

Action and function of Faecalibacterium prausnitzii in health and disease

Ferreira‐Halder, C. V., Faria, A. V. D. S., & Andrade, S. S. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.011 · Cited by 481 · see citing works

Faecalibacterium prausnitzii in Differentiated Thyroid Cancer Patients Treated with Radioiodine

Fernandes, A. R., Oliveira, A. B. F. D., Carvalho, A. L., Soares, R. A., & Barata, P. (2023) · Nutrients · doi:10.3390/nu15122680 · Cited by 15 · see citing works

The critical role of Faecalibacterium prausnitzii in human health: An overview

Leylabadlo, H. E., Ghotaslou, R., Feizabadi, M. M., Farajnia, S., Moaddab, S. Y., Ganbarov, K., Khodadadi, E., Tanomand, A., Sheykhsaran, E., Yousefi, B., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104344 · Cited by 239 · see citing works